Compare Altria Group Inc (MO) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs 22nd Century Group Inc — how do they compare? Altria Group Inc trades at $68.15 (market cap $113.83B), while 22nd Century Group Inc trades at $2.17 (market cap $1.62M). The key difference: Altria Group Inc is far larger — about 70265.4× 22nd Century Group Inc's market cap, and Altria Group Inc pays a 6.51% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| MO | XXII | |
|---|---|---|
Market Cap | $113.83B | $1.62M |
Sector | Consumer Staples | Technology |
52-Week High | $74.92 | $594.00 |
52-Week Low | $54.72 | $2.13 |
Enterprise Value | $136.04B | -$2.69M |
Dividend Yield | 6.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MO trades at $68.18, down 1.02% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing revenue expectations, and maintains a strong 6.4% dividend yield after its 57th consecutive annual increase. Cash flow from operations remains robust at $9.29 billion for 2025, supporting dividend sustainability despite regulatory headwinds.
Outlook is cautiously optimistic with a consensus price target of $68.50, reflecting Wall Street's buy-heavy ratings. Key risks include ongoing FDA litigation, declining cigarette volumes, and high debt levels. The stock offers income appeal but faces secular challenges in the tobacco industry, requiring careful monitoring of regulatory developments and smoke-free segment growth.
XXII trades at $2.29, down 4.58% today, showing continued bearish momentum with negative technical signals. The company faces severe financial challenges with negative profit margins (-76.01% net income margin) and consecutive earnings misses. Despite analyst optimism (75% buy ratings), fundamental weakness persists with declining revenue and substantial losses. Recent corporate actions include a 20:1 reverse stock split completed June 2026 to maintain listing compliance.
The outlook remains challenging given persistent operational losses and negative cash flow from operations. Investment opportunity exists if the company can capitalize on its claimed $50B market opportunity and improve gross margins. Key risks include continued cash burn, competitive pressures in tobacco alternatives, and execution challenges in commercializing VLN products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
